Sutro Biopharma (NASDAQ:STRO) Given Outperform Rating at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Sutro Biopharma (NASDAQ:STROFree Report) in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

A number of other equities analysts also recently weighed in on STRO. JMP Securities reaffirmed a market outperform rating and set a $17.00 price target on shares of Sutro Biopharma in a research note on Wednesday. HC Wainwright cut their price target on shares of Sutro Biopharma from $16.00 to $12.00 and set a buy rating on the stock in a research note on Tuesday, March 26th. Finally, Wedbush cut their price target on shares of Sutro Biopharma from $12.00 to $8.00 and set an outperform rating on the stock in a research note on Tuesday, March 26th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of Buy and an average price target of $12.57.

Check Out Our Latest Stock Analysis on STRO

Sutro Biopharma Stock Performance

Shares of STRO opened at $5.09 on Wednesday. The company has a market capitalization of $317.82 million, a price-to-earnings ratio of -2.86 and a beta of 0.95. The company’s 50 day simple moving average is $4.56 and its 200 day simple moving average is $3.81. Sutro Biopharma has a 1 year low of $2.01 and a 1 year high of $6.13.

Insider Activity

In other news, insider Nicki Vasquez sold 12,185 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $5.00, for a total value of $60,925.00. Following the transaction, the insider now owns 12,803 shares of the company’s stock, valued at approximately $64,015. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Sutro Biopharma

A number of hedge funds have recently made changes to their positions in STRO. Nisa Investment Advisors LLC raised its stake in shares of Sutro Biopharma by 14,125.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 8,820 shares of the company’s stock valued at $38,000 after acquiring an additional 8,758 shares during the period. Wells Fargo & Company MN grew its holdings in Sutro Biopharma by 331.7% during the 4th quarter. Wells Fargo & Company MN now owns 5,690 shares of the company’s stock valued at $46,000 after purchasing an additional 4,372 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in Sutro Biopharma during the 2nd quarter valued at $46,000. Tower Research Capital LLC TRC grew its holdings in Sutro Biopharma by 342.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 15,128 shares of the company’s stock valued at $52,000 after purchasing an additional 11,708 shares in the last quarter. Finally, Ergoteles LLC acquired a new stake in Sutro Biopharma during the 2nd quarter valued at $54,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

(Get Free Report)

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.

Featured Stories

Analyst Recommendations for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.